Data from registries and clinical trials have shown that nonvitamin K oral anticoagulants (NOACs) have a more favorable risk–benefit profile, compared to warfarin in primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (NVAF). Due to significant reductions in hemorrhagic stroke (RR 0.43, 95% CI 0.29–0.64) and death from any cause (RR 0.87, 95% CI 0.80–0.95), when compared to warfarin at high time in therapeutic range (TTR) levels (more than 70%), NOACs are currently the preferred anticoagulant therapy for NVAF patients [1, 2]. However, in patients prescribed oral anticoagulants, findings from clinical trials have reported annual residual risks (0.7 to 2.3%) in primary and secondary prevention of ischemic event recurrence [3]. Moreover, in the non-randomized RENo-EXTEND study, among those patients with ischemic stroke while on NOAC therapy, findings included a combined rate of thromboembolic and bleeding events equal to 16.7%, corresponding to an annual rate of 13.4% [4]. In light of the above, RCTs are needed to better understand feasible strategies for patients prescribed NOACs with stroke recurrence. The aim of this review is to provide practical suggestions on how to manage this clinical issue.

Ischemic stroke while on NOAC therapy in patients with atrial fibrillation: suggested treatment strategies

Paciaroni, Maurizio
Ultimo
Conceptualization
2023

Abstract

Data from registries and clinical trials have shown that nonvitamin K oral anticoagulants (NOACs) have a more favorable risk–benefit profile, compared to warfarin in primary and secondary prevention of stroke for patients with non-valvular atrial fibrillation (NVAF). Due to significant reductions in hemorrhagic stroke (RR 0.43, 95% CI 0.29–0.64) and death from any cause (RR 0.87, 95% CI 0.80–0.95), when compared to warfarin at high time in therapeutic range (TTR) levels (more than 70%), NOACs are currently the preferred anticoagulant therapy for NVAF patients [1, 2]. However, in patients prescribed oral anticoagulants, findings from clinical trials have reported annual residual risks (0.7 to 2.3%) in primary and secondary prevention of ischemic event recurrence [3]. Moreover, in the non-randomized RENo-EXTEND study, among those patients with ischemic stroke while on NOAC therapy, findings included a combined rate of thromboembolic and bleeding events equal to 16.7%, corresponding to an annual rate of 13.4% [4]. In light of the above, RCTs are needed to better understand feasible strategies for patients prescribed NOACs with stroke recurrence. The aim of this review is to provide practical suggestions on how to manage this clinical issue.
2023
De Magistris, Ilaria Leone; Paciaroni, Maurizio
File in questo prodotto:
File Dimensione Formato  
De Magistris.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 429.78 kB
Formato Adobe PDF
429.78 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2573270
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact